News | Drug-Eluting Balloons | March 31, 2022

Medtronic Issues Voluntary Recall for Subset of IN.PACT Admiral and IN.PACT AV Drug Coated Balloon

A subset of the IN.PACT Admiral and IN.PACT AV Paclitaxel-coated Percutaneous Transluminal Angioplasty (PTA) balloon catheters have been recalled due to the potential for pouch damage resulting in loss of sterility

In accordance with its commitment to patient safety, Medtronic recently voluntarily recalled a subset of its IN.PACT Admiral and IN.PACT AV Paclitaxel-coated Percutaneous Transluminal Angioplasty (PTA) balloon catheters due to the potential for pouch damage resulting in a loss of sterility.

The IN.PACT Admiral drug-coated balloon.


March 31, 2022 — In accordance with its commitment to patient safety, Medtronic recently voluntarily recalled a subset of its IN.PACT Admiral and IN.PACT AV Paclitaxel-coated Percutaneous Transluminal Angioplasty (PTA) balloon catheters due to the potential for pouch damage resulting in a loss of sterility.

Approximately 6,000 IN.PACT Admiral catheters and 3 IN.PACT AV catheters distributed to customers globally are impacted by this recall. Medtronic is communicating to customers with affected product on hand to immediately quarantine and return the product to Medtronic, as well as send back a signed confirmation form.  

The pouch damage was discovered during a routine inspection. Upon investigation, a change implemented to one manufacturing line was determined to be the cause. All batches manufactured on this line after that change are being retrieved. The problem on that line was fixed. Additionally, to ensure that no further issues, production on all lines was paused until a follow up packaging inspection was completed.  No further errors were discovered.

Medtronic has received zero (0) complaints involving this issue. There have been zero (0) reports of injury or death related to this issue. There are no actions required for patients where the affected IN.PACT Admiral and IN.PACT AV catheters were used during a procedure. Patients should continue to be monitored in accordance with the medical facility’s standard care protocols. 

For most regions, there is little or no impact for customers to order replacement product. Customers may reach out to Medtronic Customer service (800-551-5544, selection option “Vascular”) for any questions regarding their return or ordering replacement product.

No other Medtronic products are affected by this issue. All appropriate regulatory bodies have been notified. 

For more information: www.medtronic.com


Related Content

News | Drug-Eluting Balloons

March 1, 2024 — Boston Scientific Corporation today announced it has received U.S. Food and Drug Administration (FDA) ...

Home March 01, 2024
Home
News | Drug-Eluting Balloons

October 30, 2023 — Boston Scientific Corporation on Friday announced positive 12-month results from the pivotal AGENT ...

Home October 30, 2023
Home
News | Drug-Eluting Balloons

September 14, 2023 — BIOTRONIK announced the two-year-results from the BIOLUX P-III BENELUX all-comers registry ...

Home September 14, 2023
Home
News | Drug-Eluting Balloons

September 11, 2023 — The first patient has been enrolled in a UK study of large vessel de novo coronary artery disease ...

Home September 11, 2023
Home
News | Drug-Eluting Balloons

July 14, 2023 — BIOTRONIK announced the one-year subgroup results from the investigator-initiated BIOPACT randomized ...

Home July 14, 2023
Home
News | Drug-Eluting Balloons

May 30, 2023 — Twelve-month results from the SELUTION SFA trial have been presented for the first time at the Japan ...

Home May 30, 2023
Home
News | Drug-Eluting Balloons

May 30, 2023 — The US FDA, on the 24th of May 2023, granted an Investigational Device Exemption (IDE) approval for ...

Home May 30, 2023
Home
News | Drug-Eluting Balloons

May 12, 2023 — The US FDA has granted an Investigational Device Exemption (IDE) approval for Concept Medical Inc’s novel ...

Home May 12, 2023
Home
News | Drug-Eluting Balloons

May 4, 2023 — The first US patient has been enrolled in the SELUTION4SFA Sirolimus DEB study by Dr. Arthur Lee at the ...

Home May 04, 2023
Home
News | Drug-Eluting Balloons

April 28, 2023 — Medtronic today shared additional 36-month data from the IN.PACT AV Access Study, as well as 48-month ...

Home April 28, 2023
Home
Subscribe Now